Fianlimab

Monoclonal antibody

Phase 3topline reported

Evidence outlook · registrational

Melanoma: topline reported 2026-05

No completed mid-stage readout is on record. The sponsor reported topline results in 2026-05 (Phase 3 fianlimab plus Libtayo versus pembrolizumab in first-line melanoma missed its PFS primary endpoint). The announcement is listed under Regulatory events.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (3)
Phase 2/3 (2)
Other / comorbidity
NCT05800015 · Regeneron Pharmaceuticals
2023-08-08 – 2031-12-23 · Non-small Cell Lung Cancer
What this study did
NCT05785767 · Regeneron Pharmaceuticals
2023-06-30 – 2027-09-28 · Advanced Non-Small Cell Lung Cancer
What this study did
Phase 2 (27)
Melanoma
NCT06190951 · Regeneron Pharmaceuticals
2024-09-18 – 2030-12-09 · Melanoma
What this study did
NCT06848088 · Regeneron Pharmaceuticals
2025-04-14 – 2030-10-09 · Melanoma
What this study did
NCT07511036 · M.D. Anderson Cancer Center
2026-09-01 – 2030-05-24 · Melanoma
What this study did
NCT07527325 · University of California, Irvine
2026-12 – 2030-02-01 · Melanoma (Skin)
What this study did
NCT06887088 · Grupo Español Multidisciplinar de Melanoma
2025-05-29 – 2028-01 · Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases
What this study did
NCT06594991 · Memorial Sloan Kettering Cancer Center
2024-09-10 – 2027-09 · Advanced Melanoma
What this study did
Other / comorbidity
NCT06918132 · Mayo Clinic
2025-05-02 – 2033-12-02 · Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
What this study did
NCT01042379 · QuantumLeap Healthcare Collaborative
2010-03-01 – 2031-12 · Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07346196 · University of Chicago
2027-02-07 – 2031-08-22 · Squamous Cell Carcinoma
What this study did
NCT07223541 · University of Oklahoma
2026-01-15 – 2031-08 · Clear Cell Renal Cell Carcinoma
What this study did
NCT05929664 · Thomas Jefferson University
2023-07-05 – 2031-07-05 · Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma
What this study did
NCT06769698 · Regeneron Pharmaceuticals
2026-04-14 – 2030-12-28 · Head and Neck Squamous Cell Carcinoma (HNSCC)
What this study did
NCT07188896 · Brian Rini
2026-04-29 – 2030-11-30 · Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC), Clear Cell Renal Cell Carcinoma (ccRCC)
What this study did
NCT07808515 · Regeneron Pharmaceuticals
2026-11-13 – 2030-11-13 · Locally Advanced Basal Cell Carcinoma
What this study did
NCT07281768 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2026-07-14 – 2030-07 · Colorectal Cancer
What this study did
NCT07224022 · John Strickler, M.D.
2027-03-01 – 2030-06-30 · Colon Cancer
What this study did
NCT03916627 · Regeneron Pharmaceuticals
2019-07-23 – 2030-05-14 · Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
What this study did
NCT06384820 · Regeneron Pharmaceuticals
2024-11-14 – 2030-05-06 · Cutaneous Squamous Cell Carcinoma
What this study did
NCT06205836 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2024-06-13 – 2030-05 · Colorectal Cancer
What this study did
NCT07179315 · University of Chicago
2026-06-09 – 2029-11-30 · Head and Neck Cancer
What this study did
NCT07234058 · Intergroupe Francophone de Cancerologie Thoracique
2026-04-02 – 2029-09 · Pleural Mesotheliomas
What this study did
NCT06787612 · Regeneron Pharmaceuticals
2025-05-28 – 2028-06-30 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
What this study did
NCT07414992 · Memorial Sloan Kettering Cancer Center
2026-09 – 2028-03 · Bladder Urothelial Carcinoma
What this study did
NCT06699602 · Memorial Sloan Kettering Cancer Center
2025-02-11 – 2028-02 · Renal Cell Carcinoma
What this study did
NCT06865339 · Montefiore Medical Center
2025-08-07 – 2027-08 · NSCLC, Locally Advanced
What this study did
NCT06571708 · Columbia University
2025-08-14 – 2026-01-05 · Bladder Cancer, Muscle-Invasive Bladder Carcinoma
What this study did
Phase 1/2 (4)
Other / comorbidity
NCT07567469 · Regeneron Pharmaceuticals
2026-08-31 – 2034-08-17 · High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma
What this study did
NCT04989946 · University of Wisconsin, Madison
2021-12-16 – 2028-12 · Prostate Cancer
What this study did
NCT04590326 · Regeneron Pharmaceuticals
2020-12-08 – 2028-11-08 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
What this study did
NCT04706715 · University Medical Center Groningen
2022-01-18 – 2025-11 · Metastatic Solid Tumor
What this study did
Phase 1 (5)
Other / comorbidity
NCT07365839 · Virginia Commonwealth University
2026-10-01 – 2035-05-28 · Hepatocellular Carcinoma
What this study did
NCT03233139 · Regeneron Pharmaceuticals
2017-06-21 – 2027-09-30 · Advanced Malignancies
What this study did
NCT04566978 · Memorial Sloan Kettering Cancer Center
2020-09-11 – 2025-03-21 · Large B-cell Lymphoma, DLBCL
What this study did
NCT03005782 · Regeneron Pharmaceuticals
2016-11-07 – 2024-04-02 · Malignancies
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (1)
Phase 1 (1)
Other / comorbidity
NCT07650266 · Memorial Sloan Kettering Cancer Center
2026-12 – 2030-07 · Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Carcinoma, Nasopharynx Cancer
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Melanoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Fianlimab: this drugPhase 3Monoclonal antibodyLAG-3not yet gradedNo reviewed efficacy summary in this indication
Aldesleukin (Proleukin)ApprovedRecombinant Cytokine (il-2)Interleukin-2 receptor (IL-2R)not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BinimetinibApprovedSmall moleculeMEK1/2Partial signal
NCT01763164: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)): Binimetinib (MEK162) 2.83 Months (95% CI 2.76 to 3.55) | Dacarbazine 1.51 Months (95% CI 1.48 to 1.71)
CobimetinibApprovedSmall moleculeMEK1/2Reliable signalNo reviewed efficacy summary in this indication
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Reliable signal
NCT01597908: Overall Survival (OS) (From the date of randomization until date of death due to any cause (up to approximately 6 years)): Dabrafenib Plus Trametinib 26 Months (95% CI 22.1 to 33.8) | Vemurafenib 17.8 Months (95% CI 15.6 to 20.7)
NCT01584648: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)): Dabrafenib + Trametinib 10.2 Months (95% CI 8.1 to 12.8) | Dabrafenib + Placebo 8.8 Months (95% CI 5.9 to 9.3)
EncorafenibApprovedSmall moleculeBRAF V600EPartial signalNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptorPartial signal
NCT01359956: Overall survival, interferon alfa-2b added vs not added to dacarbazine-based chemotherapy (2x2 factorial): HR 0.92 (95% CI 0.70 to 1.20), p=0.68 (Daponte et al., J Transl Med 2013). missed
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT00094653: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone (From randomization until the end of the study, which was defined as the time at which 481 deaths were observed (264 weeks)): Ipilimumab Plus gp100 9.95 months (95% CI 8.48 to 11.5) | gp100 6.44 months (95% CI 5.49 to 8.71)
Lifileucel (Amtagvi)ApprovedCell therapyTumor-infiltrating lymphocytes (polyclonal tumor antigens)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02388906: Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09)
NCT01721746: CheckMate 037 coprimaries: objective response rate 31.7% (95% CI 23.5 to 40.8) in the first 120 nivolumab patients vs 10.6% (3.5 to 23.1) with investigator-choice chemotherapy at the interim analysis, reported without a between-group p-value; overall survival median 16 vs 14 months (HR 0.95, 95.54% CI 0.73 to 1.24), no difference (Weber, Lancet Oncol 2015; Larkin, JCO 2018). missed
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
RelatlimabApprovedMonoclonal antibodyLAG-3Reliable signal
NCT03470922: Progression Free Survival (PFS) (From randomization to date of first documented tumor progression or death (up to approximately 33 months)): Arm A: Relatlimab + Nivolumab 10.12 Months (95% CI 6.37 to 15.74) | Arm B: Nivolumab 4.63 Months (95% CI 3.38 to 5.62)
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
TrametinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
VemurafenibApprovedSmall moleculeBRAF (V600 mutant)Partial signalNo reviewed efficacy summary in this indication
Vusolimogene Oderparepvec (Tudriqev)ApprovedOncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
CemiplimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Intismeran AutogenePhase 3VaccinePatient-specific tumor neoantigens (personalized, up to 34 per patient)not yet gradedNo reviewed efficacy summary in this indication
Tebentafusp-Tebn (KIMMTRAK)Phase 3Protein / enzyme therapeuticgp100-HLA-A*02:01 x CD3Partial signalNo reviewed efficacy summary in this indication
LNS8801Phase 2/3Small moleculeGPER (G protein-coupled estrogen receptor)not yet gradedNo reviewed efficacy summary in this indication
ResiquimodPhase 2/3Small moleculeToll-like receptor 7 and 8 (TLR7/8)not yet gradedNo reviewed efficacy summary in this indication
HLX26
Phase 2(overall)
Monoclonal antibodyLAG-3
not yet graded(overall)
No reviewed efficacy summary in this indication
HS-IT101Phase 2Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
VSV-IFNβ-NISPhase 2Oncolytic virusOncolytic VSV expressing interferon-beta and NISnot yet gradedNo reviewed efficacy summary in this indication
EvalstotugPhase 1/2Biologic (subtype unspecified)CTLA-4not yet gradedNo reviewed efficacy summary in this indication
OBX-115Phase 1/2Cell therapyIL-15 receptor signalingnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
GSK2831781
Discontinued
Monoclonal antibodyLAG-3
not yet graded(overall)
No reviewed efficacy summary in this indication
NaporafenibDiscontinuedSmall moleculePan-RAFnot yet gradedNo reviewed efficacy summary in this indication

Compare side by side

Upcoming events

(29 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Fianlimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1/2Prostate CancerActive not recruiting
Est. primary completion 2026-12 · NCT04989946 · CT.gov ↗
What to watch
2027 (6)
January 2027 (1)
Phase 3MelanomaActive not recruiting
Est. primary completion 2027-01-15 · NCT05608291 · CT.gov ↗
What to watch
March 2027 (1)
Phase 3MelanomaRecruiting
Est. primary completion 2027-03-22 · NCT06246916 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2NSCLC, Locally AdvancedRecruiting
Est. primary completion 2027-08 · NCT06865339 · CT.gov ↗
What to watch
September 2027 (3)
Phase 2MelanomaRecruiting
Est. primary completion 2027-09 · NCT06594991 · CT.gov ↗
What to watch
Phase 2/3Advanced Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09-28 · NCT05785767 · CT.gov ↗
What to watch
Phase 1Advanced MalignanciesActive not recruiting
Est. primary completion 2027-09-30 · NCT03233139 · CT.gov ↗
What to watch
2028 (8)
January 2028 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2028-01 · NCT06887088 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2028-02 · NCT06699602 · CT.gov ↗
What to watch
March 2028 (1)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-25 · NCT05137054 · CT.gov ↗
What to watch
May 2028 (2)
Phase 2Pleural MesotheliomasRecruiting
Est. primary completion 2028-05 · NCT07234058 · CT.gov ↗
What to watch
Phase 2MelanomaNot yet recruiting
Est. primary completion 2028-05-24 · NCT07511036 · CT.gov ↗
What to watch
June 2028 (2)
Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC)Recruiting
Est. primary completion 2028-06-04 · NCT06769698 · CT.gov ↗
What to watch
Phase 2Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal CancerRecruiting
Est. primary completion 2028-06-30 · NCT06787612 · CT.gov ↗
What to watch
November 2028 (1)
Phase 1/2Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial CancerRecruiting
Est. primary completion 2028-11-08 · NCT04590326 · CT.gov ↗
What to watch
2029 (5)
February 2029 (1)
Phase 2MelanomaNot yet recruiting
Est. primary completion 2029-02-01 · NCT07527325 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Clear Cell Renal Cell CarcinomaRecruiting
Est. primary completion 2029-08 · NCT07223541 · CT.gov ↗
What to watch
November 2029 (2)
Phase 2Head and Neck CancerRecruiting
Est. primary completion 2029-11-30 · NCT07179315 · CT.gov ↗
What to watch
Phase 2Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC), Clear Cell Renal Cell Carcinoma (ccRCC)Recruiting
Est. primary completion 2029-11-30 · NCT07188896 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Colon CancerNot yet recruiting
Est. primary completion 2029-12-31 · NCT07224022 · CT.gov ↗
What to watch
2030 (7)
January 2030 (1)
Phase 2/3Non-small Cell Lung CancerActive not recruiting
Est. primary completion 2030-01-16 · NCT05800015 · CT.gov ↗
What to watch
May 2030 (1)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2030-05 · NCT06205836 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2030-07 · NCT07281768 · CT.gov ↗
What to watch
October 2030 (1)
Phase 2MelanomaActive not recruiting
Est. primary completion 2030-10-09 · NCT06848088 · CT.gov ↗
What to watch
November 2030 (1)
Phase 2Locally Advanced Basal Cell CarcinomaNot yet recruiting
Est. primary completion 2030-11-13 · NCT07808515 · CT.gov ↗
What to watch
December 2030 (2)
Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
Phase 2Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8 …Recruiting
Est. primary completion 2030-12-02 · NCT06918132 · CT.gov ↗
What to watch
2031 (1)
August 2031 (1)
Phase 2Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2031-08-22 · NCT07346196 · CT.gov ↗
What to watch
2032 (1)
August 2032 (1)
Phase 1/2High-Grade Glioma (HGG), Posterior Fossa-A EpendymomaNot yet recruiting
Est. primary completion 2032-08-27 · NCT07567469 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

May 2026Topline resultPhase 3 fianlimab plus Libtayo versus pembrolizumab in first-line melanoma missed its PFS primary endpoint